WO2017133429A1 - 一种萜品烯醇类化合物及其制备方法和应用 - Google Patents
一种萜品烯醇类化合物及其制备方法和应用 Download PDFInfo
- Publication number
- WO2017133429A1 WO2017133429A1 PCT/CN2017/071217 CN2017071217W WO2017133429A1 WO 2017133429 A1 WO2017133429 A1 WO 2017133429A1 CN 2017071217 W CN2017071217 W CN 2017071217W WO 2017133429 A1 WO2017133429 A1 WO 2017133429A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- terpineol
- compound
- compound according
- membered
- alkyl
- Prior art date
Links
- HUUPVABNAQUEJW-UHFFFAOYSA-N CN(CC1)CCC1=O Chemical compound CN(CC1)CCC1=O HUUPVABNAQUEJW-UHFFFAOYSA-N 0.000 description 1
- BAUWRHPMUVYFOD-UHFFFAOYSA-N CN(CC1)CCC1O Chemical compound CN(CC1)CCC1O BAUWRHPMUVYFOD-UHFFFAOYSA-N 0.000 description 1
- CRVGTESFCCXCTH-UHFFFAOYSA-N CN(CCO)CCO Chemical compound CN(CCO)CCO CRVGTESFCCXCTH-UHFFFAOYSA-N 0.000 description 1
- YCQHTIDVLROXSL-UHFFFAOYSA-N IN1CCOCC1 Chemical compound IN1CCOCC1 YCQHTIDVLROXSL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C203/00—Esters of nitric or nitrous acid
- C07C203/02—Esters of nitric acid
- C07C203/04—Esters of nitric acid having nitrate groups bound to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/02—Formation of carboxyl groups in compounds containing amino groups, e.g. by oxidation of amino alcohols
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
- C07C229/12—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C29/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
- C07C29/17—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by hydrogenation of carbon-to-carbon double or triple bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C29/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
- C07C29/17—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by hydrogenation of carbon-to-carbon double or triple bonds
- C07C29/172—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by hydrogenation of carbon-to-carbon double or triple bonds with the obtention of a fully saturated alcohol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C291/00—Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00
- C07C291/02—Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00 containing nitrogen-oxide bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C31/00—Saturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
- C07C31/13—Monohydroxylic alcohols containing saturated rings
- C07C31/133—Monohydroxylic alcohols containing saturated rings monocyclic
- C07C31/135—Monohydroxylic alcohols containing saturated rings monocyclic with a five or six-membered rings; Naphthenic alcohols
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
- C07C319/14—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides
- C07C319/20—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides by reactions not involving the formation of sulfide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/14—Preparation of carboxylic acid esters from carboxylic acid halides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
- C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
- C07C69/24—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with monohydroxylic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/04—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
Definitions
- the invention belongs to the field of biomedicine, and particularly relates to a terpene enol compound and a preparation method and application thereof.
- Ai leaf oil is a volatile oil contained in the dry leaves or fresh leaves of Artemisia argyi. It can directly relax the smooth muscle of the trachea and has protective effects on antigen, acetylcholine and histamine-induced tracheal smooth muscle spasm and asthma. It also has anti-allergic effects, can inhibit the release of allergic slow-reactive substances (SRS-A) in sensitized lung tissue, and can antagonize the effects of SRS-A and serotonin. It also has a certain expectorant and antitussive effect. No excitatory effects on the heart, mainly used for bronchial asthma and asthma-type chronic bronchitis.
- SRS-A allergic slow-reactive substances
- ⁇ -terpineol is an antiasthmatic active ingredient extracted from eucalyptus oil, and its chemical name is ⁇ , ⁇ ,4-trimethyl--3-cyclohexene-1-methanol.
- Ru Ru et al. reported the pharmacological effects of ⁇ -terpineol ("Pharmacological action of new antiasthmatic drug- ⁇ -terpineol", Chinese Journal of Pharmacology, vol. 3, No. 6, 1987, pp. 323 ⁇ Page 328), it was found that ⁇ -terpineol has airway relaxation in guinea pig whole and ex vivo experiments, can increase cAMP content in tracheal smooth muscle, anti-allergic, antitussive and expectorant effects, and low toxicity. A safe and effective new antiasthmatic drug.
- ⁇ -terpineol is different from the beta agonist and has an inhibitory effect on the isolated atrium of guinea pigs.
- Chinese Patent Application Publication No. CN 103922927 A discloses an ⁇ -terpene enol derivative and a preparation method and application thereof, and the structure of the ⁇ -terpene enol derivative is as follows:
- R is selected from a C 1 -C 5 alkyl group, and the anti-asthmatic activity is enhanced to a certain extent by derivatization of ⁇ -nonanol, but the antiasthmatic activity is still not good enough.
- the invention provides a terpene enol compound and a preparation method and application thereof, the terpene enol compound having better anti-asthmatic activity and having certain anti-inflammatory activity.
- R is independently selected from C 12 -C 16 alkyl, -NR 1 R 2 , -SR 3 or -OR 4 ;
- R 1 , R 2 , R 3 and R 4 are independently selected from C 1 -C 6 alkyl or -NO 2 , and the C 1 -C 6 alkyl group may be substituted by OH;
- the activity test shows that the terpineol compound of the present invention can effectively relax bronchial smooth muscle, reduce inflammatory cells, and effectively relieve pulmonary hypertension.
- the R is -NR 1 R 2 , and in this case, the terpineol compound can form a pharmaceutically acceptable salt with an acid, is more easily dissolved in water, and is convenient for pharmaceutical applications.
- said R is one of C 12 H 25 , C 16 H 33 or the like:
- the present invention also provides a process for preparing the terpene enol compound.
- the preparation method comprises the following steps:
- the ⁇ -terpineol is reacted with alkanoyl chloride in dichloromethane under the action of pyridine, and the terpene enol compound is obtained after completion of the reaction;
- the alkanoyl chloride is a C 14 -C 16 alkanoyl chloride.
- the esterification intermediate obtained in the step (1) and a nucleophilic reagent are subjected to a substitution reaction in acetonitrile to obtain the terpinenol compound;
- the nucleophile is HNR 1 R 2 , HSR 3 or HOR 4 .
- the preparation method comprises the following steps:
- the ⁇ -terpineol is subjected to hydrogenation reaction in methanol under a hydrogen atmosphere of Pd/C to obtain the terpene enol compound.
- the invention also provides the use of the terpene enol compound in the pharmaceutical field.
- the terpineol compound is used for preparing an anti-asthma drug
- the anti-asthmatic drug is used to relax the bronchi.
- the test results show that the terpineol compound can also effectively reduce the number of inflammatory cells.
- the terpineol compound is used for the preparation of an anti-inflammatory drug.
- the terpineol compound is used for the preparation of a medicament for treating or ameliorating pulmonary hypertension.
- the present invention effectively enhances the anti-asthmatic action and anti-pulmonary hypertension effect of such compounds by derivatizing the terpineol compounds;
- the terpineol compound of the present invention can reduce inflammatory cells and has good anti-inflammatory activity.
- a rat asthma model was established. After the last administration, the trachea was isolated bluntly, bronchoalveolar lavage was performed, bronchial cell lavage fluid (BALF) was collected, and the total number of nucleated cells was counted. The results are shown in Table 2.
- compound N is the product structure.
- ⁇ ⁇ indicates that compared with the blank group, P ⁇ 0.01; ⁇ indicates that compared with the blank group, P ⁇ 0.05;
- Each compound group can expand the relaxation rate of tracheal smooth muscle at different doses, and has an inhibitory effect on inflammation. It can be used for inflammation treatment of asthma, chronic obstructive pulmonary disease and various other diseases, such as arthritis, rheumatoid arthritis, bronchitis, allergic rhinitis, allergic dermatitis and the like.
- the normal control group was given an equal volume of normal saline.
- drug intervention was given, and each compound was administered 200 mg/Kg daily; the normal control group and the model group were given an equal volume of normal saline per day.
- the right ventricular systolic pressure was measured by right heart catheterization under anesthesia, and the results are shown in Table 3.
- each compound had a protective effect on monocrotaline-induced pulmonary hypertension in rats, which could improve hemodynamic parameters, reduce right ventricular systolic pressure, reduce right ventricular load, reduce right heart hypertrophy index, and relieve pulmonary vascular remodeling. .
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Description
Claims (9)
- 一种如权利要求1所述的萜品烯醇类化合物的制备方法,其特征在于,包括以下步骤:在吡啶的作用下,将α-萜品烯醇与烷酰氯在二氯甲烷中进行反应,反应完成后得到所述的萜品烯醇类化合物;所述的烷酰氯为C14~C16烷酰氯,所述的R为C12~C16烷基。
- 一种如权利要求1所述的萜品烯醇类化合物的制备方法,其特征 在于,包括以下步骤:(1)在吡啶的作用下,α-萜品烯醇与溴乙酰溴在二氯甲烷中发生酯化反应,得到酯化中间体;(2)在无机碱的作用下,步骤(1)得到的酯化中间体与亲核试剂在乙腈中发生取代反应,得到所述的萜品烯醇类化合物;所述的亲核试剂为HNR1R2、HSR3或HOR4。
- 一种如权利要求1所述的萜品烯醇类化合物的制备方法,其特征在于,包括以下步骤:在Pd/C和氢气氛围下,α-萜品烯醇在甲醇中进行加氢反应,得到所述的萜品烯醇类化合物;所述的萜品烯醇类化合物为式(Ⅱ)所示的化合物。
- 一种如权利要求1或2所述的萜品烯醇类化合物在制药领域中的应用。
- 根据权利要求6所述的萜品烯醇类化合物在制药领域中的应用,其特征在于,所述的萜品烯醇类化合物用于制备抗哮喘药物;所述的抗哮喘药物用于舒张支气管。
- 根据权利要求6所述的萜品烯醇类化合物在制药领域中的应用,其特征在于,所述的萜品烯醇类化合物用于制备抗炎药物。
- 根据权利要求6所述的萜品烯醇类化合物在制药领域中的应用,其特征在于,所述的萜品烯醇类化合物用于制备治疗或者缓解肺动脉高压的药物。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018558468A JP6668508B2 (ja) | 2016-02-04 | 2017-01-16 | テルピネオール類化合物およびその調製方法と使用 |
US16/074,403 US11117866B2 (en) | 2016-02-04 | 2017-01-16 | Terpineol and preparation method and application thereof |
EP17746749.5A EP3412649B1 (en) | 2016-02-04 | 2017-01-16 | Terpineol and preparation method and application thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610079970.4A CN106380400B (zh) | 2016-02-04 | 2016-02-04 | 一种萜品烯醇类化合物及其制备方法和应用 |
CN201610079970.4 | 2016-02-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017133429A1 true WO2017133429A1 (zh) | 2017-08-10 |
Family
ID=57916542
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2017/071217 WO2017133429A1 (zh) | 2016-02-04 | 2017-01-16 | 一种萜品烯醇类化合物及其制备方法和应用 |
Country Status (5)
Country | Link |
---|---|
US (1) | US11117866B2 (zh) |
EP (1) | EP3412649B1 (zh) |
JP (1) | JP6668508B2 (zh) |
CN (1) | CN106380400B (zh) |
WO (1) | WO2017133429A1 (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102416154A (zh) * | 2011-12-08 | 2012-04-18 | 汪科元 | 一种沉香保健香囊 |
WO2013034416A1 (en) * | 2011-09-09 | 2013-03-14 | Unilever N.V. | Antimicrobial method and composition |
CN103922927A (zh) * | 2014-04-01 | 2014-07-16 | 浙江省中医药研究院 | α-萜品烯醇衍生物及其制备方法和应用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0733656A (ja) * | 1993-07-23 | 1995-02-03 | Sagami Chem Res Center | 免疫賦活剤 |
JP3572115B2 (ja) * | 1994-06-02 | 2004-09-29 | 塩野義製薬株式会社 | 2−ピラノン誘導体及びそれを含有する免疫抑制剤 |
JPH0952854A (ja) * | 1995-08-09 | 1997-02-25 | Kao Corp | α−ジヒドロテルピネオールの製造方法 |
JP2003212763A (ja) * | 2002-01-16 | 2003-07-30 | Toyama Prefecture | 気管支拡張剤 |
JP4662134B2 (ja) * | 2005-05-09 | 2011-03-30 | ヤスハラケミカル株式会社 | 導電性ペースト |
EA016931B1 (ru) * | 2007-07-20 | 2012-08-30 | Тойо Суйсан Кайся, Лтд. | Новое сульфированное соединение сахара и его применение в качестве лекарственного средства |
CN104447313B (zh) * | 2015-01-07 | 2016-04-13 | 河北联合大学 | α-萜品醇脂肪酸酯衍生物及应用 |
-
2016
- 2016-02-04 CN CN201610079970.4A patent/CN106380400B/zh active Active
-
2017
- 2017-01-16 JP JP2018558468A patent/JP6668508B2/ja active Active
- 2017-01-16 EP EP17746749.5A patent/EP3412649B1/en active Active
- 2017-01-16 WO PCT/CN2017/071217 patent/WO2017133429A1/zh active Application Filing
- 2017-01-16 US US16/074,403 patent/US11117866B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013034416A1 (en) * | 2011-09-09 | 2013-03-14 | Unilever N.V. | Antimicrobial method and composition |
CN102416154A (zh) * | 2011-12-08 | 2012-04-18 | 汪科元 | 一种沉香保健香囊 |
CN103922927A (zh) * | 2014-04-01 | 2014-07-16 | 浙江省中医药研究院 | α-萜品烯醇衍生物及其制备方法和应用 |
Non-Patent Citations (2)
Title |
---|
BIAN, RULIAN ET AL.: "THE PHARMACOLOGICAL PROPERTIES OF A NEW ANTIASTHMATIC DRUG, a-TERPINEOL", CHINESE PHARMACOLOGICAL BULLETIN, vol. 3, no. 6, 31 December 1987 (1987-12-31), pages 323 and 326, XP009507861, ISSN: 1001-1978 * |
See also references of EP3412649A4 * |
Also Published As
Publication number | Publication date |
---|---|
JP2019506452A (ja) | 2019-03-07 |
CN106380400B (zh) | 2018-12-11 |
EP3412649A1 (en) | 2018-12-12 |
US11117866B2 (en) | 2021-09-14 |
EP3412649A4 (en) | 2019-02-20 |
EP3412649B1 (en) | 2020-03-04 |
CN106380400A (zh) | 2017-02-08 |
US20190337900A1 (en) | 2019-11-07 |
JP6668508B2 (ja) | 2020-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1339717A1 (de) | Neue carbamat-substituierte pyrazolopyridinderivate | |
PT92303B (pt) | Processo para a preparacao de derivados de xantina | |
WO2016015479A1 (zh) | β-榄香烯13位衍生物及其治疗动脉粥样硬化的用途 | |
NO325685B1 (no) | Substituerte (1,3-bis(cycloheksylmetyl)-1,2,3,6-tetrahydro-2,6-diokso-9H-purin-8-yl)fenylderivater, fremstilling og anvendelse derav samt farmasoytisk blanding. | |
JPS63502179A (ja) | 新規なアリ−ル誘導体類 | |
CN107118250B (zh) | 一种no供体型齐墩果酸衍生物及其制备方法和用途 | |
JP6126204B2 (ja) | プロスタグランジンを主成分とした気管支拡張剤 | |
WO2017133429A1 (zh) | 一种萜品烯醇类化合物及其制备方法和应用 | |
JP2010526812A (ja) | 炎症性疾患の治療のためのスピロ化合物 | |
JP2019504178A (ja) | シクロデキストリンを主体とするポリマー、その方法、組成物、及び応用 | |
JPS6246554B2 (zh) | ||
CN104311622B (zh) | 一种积雪草酸酰胺类衍生物 | |
US11447522B2 (en) | Potent soft anti-inflammatory corticosteroid compounds and uses thereof | |
CN115746079B (zh) | 一种薯蓣皂苷元衍生物及其制备方法与用途 | |
JP7348214B2 (ja) | Hdac6選択的阻害剤の結晶形及びその使用 | |
JPH0386824A (ja) | ジテルペン系化合物及びこれを有効成分とする抗炎症剤 | |
CN109928986A (zh) | 1-o-乙酰基大花旋覆花内酯螺芳基异恶唑啉衍生物及其医药用途 | |
WO2018050099A1 (zh) | 二醇型人参皂苷衍生物及其制备方法和应用 | |
WO2022022678A1 (zh) | 一种吡嗪类化合物及其制备方法和应用 | |
WO2022228577A1 (zh) | 一种新型苯并酮类衍生物及其制备方法和应用 | |
JP2002536454A (ja) | 新規ギムネマ酸誘導体、その製造、それらを含む医薬組成物、およびそれらの医薬的使用 | |
JP2016017062A (ja) | 抗癌剤 | |
CN117756798A (zh) | 一种异丙托溴铵新晶体及其制备方法 | |
JP2021531343A (ja) | Ask1阻害剤としての結晶形、その製造方法及び利用 | |
CN108383838A (zh) | 一种酰胺类衍生物及其在高血压、高血脂和动脉粥样硬化中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17746749 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2018558468 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2017746749 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2017746749 Country of ref document: EP Effective date: 20180904 |